Capricor Therapeutics shares are trading higher after the company announced intent to file a biologics license application for the full approval of Deramiocel for the treatment of Duchenne muscular dystrophy cardiomyopathy.
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics shares rose following the announcement of their plan to file a biologics license application for Deramiocel, aimed at treating Duchenne muscular dystrophy cardiomyopathy.
September 24, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics shares increased after announcing plans to file a biologics license application for Deramiocel, targeting Duchenne muscular dystrophy cardiomyopathy.
The announcement of filing for a biologics license application is a significant step towards the commercialization of Deramiocel, which could lead to increased revenue and market presence for Capricor Therapeutics. This positive development is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100